As shown in Figure 8A, treatment with combination class II HER2-DC1 and anti-PD-1 antibody significantly delayed tumor growth compared to single treatments alone (p < 0.03) while combination therapy of class II HER2-DC1 with anti-PD-1 antibody further delayed tumor growth and survival (Figures 8A,B; p < 0.002). Here, ERBB2 is linked to neoplasm.